KEAP1 and cancer: The combined alteration of KEAP1-PTPRT, PTPRD-PTPRT-TP53, and PTPRT-TP53 was significantly higher in metastatic NSCLC than in primary cancer (Figure 4(d), q = 0.02, q = 0.0097, and q = 1.68E − 07, respectively).